Cambridge, UK, 21st November 2022: Babraham Research Campus Ltd, which is responsible for the development and management of the Babraham Research Campus is delighted to announce the appointment of Dr Kathryn Chapman to the newly created role of Director, Science & Entrepreneurship. |
News
Cambridge, UK, 10 November 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with the pharmaceutical division of one of the world’s largest chemicals marketing and pharmaceuticals companies, which focuses on the development and commercialisation of speciality drugs.
Leading global drug development consultancy Boyds has appointed experienced regulatory affairs professional and cell and gene therapy expert Dr Patrick Ginty.
With 17 years’ R&D and regulatory affairs experience in regenerative medicine and cell and gene therapy products, Patrick joins Boyds as Senior Director of Regulatory Affairs.
Cambridge, UK, 15th November 2022 / Sciad Newswire / Domainex Ltd., a leading provider of integrated drug discovery services, is pleased to announce that it has made a number of strategic internal promotions to strengthen its Executive and Management teams. This expansion marks a period of ongoing growth for Domainex, and the newly bolstered teams will be pivotal in driving further development of the company.
A collaboration to improve disease resistance in major crops through bioengineered proteins
Norwich, UK – 14 November 2022 – Leaf Expression Systems (Leaf), a contract research and development organisation that produces high value proteins and biomolecules using its innovative plant-based expression system today announced a collaboration with the John Innes Centre.
London BioScience Innovation Centre to be first occupier at Tribeca, London
The London BioScience Innovation Centre (“LBIC”) will open a new 37,127 sq. ft. state-of-the-art innovation centre at The Apex, one of five mixed-use buildings within the ‘Tribeca’ development in the heart of King’s Cross being delivered by Reef Group and Blackrock Alternatives, through its Real Estate business.
Traditionally creating optimized, stable cell lines has been a time-consuming and complex process. Drawing upon proprietary technology - AMSBIO can deliver the high-quality cell lines you need with a single customer-defined knock-in in just 25% of the time required with conventional approaches.
Using a patented FAST-HDR plasmid vector system – AMSBIO can dramatically speed vector construction and reduce the time required to successfully isolate modified clones following transfection.
NRG Therapeutics Announces £16 million Series A to Advance Mitochondrial Therapeutics for Parkinson’s and ALS
Oxford, UK, 8 November 2022 –global techbio company PrecisionLife, pioneers in precision medicine for chronic diseases, will assess the precision medicine potential of a neuroscience target nominated by Sosei Heptares, an international biopharmaceutical group specialising in structure-based drug design targeting G protein-coupled receptors (GPCRs).
o2h discovery is pleased to announce Azadyne as a winner of the o2h Kickstarter competition. Azadyne’s approach has shown striking efficacy in pre-clinical studies via the tRNA guanine transglycosylase (TGT) enzyme pathway against a range of autoimmune diseases without interfering with the body’s immune system.
As part of the kickstarter programme, o2h discovery will be providing small molecule synthetic chemistry to deliver improved medicines for patients with autoimmune disease, including Multiple Sclerosis.